In this study, we investigated the four representative tumors, including osteosarcoma, prostate, cervical and lung cancers, and uncovered that ACLY is directly downregulated by miR-22, which has implications for the potential therapeutic disruption of tumor development and progression. Here, ACLY is linked to osteosarcoma.